
-
TScan Therapeutics NASDAQ:TCRX TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Location: | Website: www.tscan.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-102.2M
Cash
290.1M
Avg Qtr Burn
-27.71M
Short % of Float
4.89%
Insider Ownership
0.24%
Institutional Own.
90.61%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 1 Data readout | ||
TSC-100 & TSC-101 Details Acute Myeloid Leukemia (AML), Acute lymphoblastic leukemia (ALL), Myelodysplastic syndrome (MDS) | Phase 1 Data readout |